Paxlovid

The new booster, available since September, is effective against the currently dominant SARS-CoV-2 variant in the U.S., JN.1.

We are approaching the two-year anniversary of the Emergency Use Authorization (EUA) of Paxlovid, the most effective COVID-19 antiviral drug.

The FDA is the nation’s most ubiquitous regulatory agency, responsible for overseeing products – drugs, medical devices, tobacco products, and most foods -- that account for about 20 cents of every dollar consumers spend.  It is currently goi

The New England Journal of Medicine (NEJM) is perhaps the world’s most prestigious medical journal, so it is both interesting and informative to see its editors’ compilation of what they consider its “notable articles” of the previous year. T

The COVID-19 pandemic rages on, in spite of pronouncements to the contrary by President Biden and some media armchair experts. Total hospitalizations in the U.S.

If there is a single lesson to be learned from three years of the pandemic, it's that if you're going to try to treat Covid with a drug, it had better be a direct-acting antiviral drug. (1)

5. Susan Goldhaber returns with an article on science in the courtroom, specifically that perennial toxic bad boy, glyphosate. There is a great deal of science, epidemiology, and statistics to understand why glyphosate is or is not a carcinogen.

Paxlovid, the most widely prescribed drug to treat symptomatic COVID-19, has lately attracted a number of detractors.

An important drug from a giant drug company is bound to have a target on its back. Lately, this has been the case with Pfizer's Paxlovid.

Decades ago, a case report (relating the experience with a single patient) was published, which described how a person’s flu symptoms improved after a bowl of chicken soup, but then reappeared. The article was meant as a kind of parody of the